IGF::OT::IGF: SBIR PHASE II, TOPIC 331: OPTICAL BIOSENSOR FOR REAL-TIME ASSESSMENT OF TUMOR CELLULARITY DURING CORE NEEDLE BIOPSY PROCEDURES.

IGF::OT::IGF：SBIR 第二阶段，主题 331：用于在芯针活检过程中实时评估肿瘤细胞性的光学生物传感器。

• 批准号: 9360347
• 负责人: NICUSOR IFTIMIA
• 金额: $ 149.97万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2018-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9360347
• 关键词: Address; Animal Cancer Model; Biopsy; Biosensor; Cellularity; Clinical; Core Biopsy; Detection; Fibrosis; Goals; Inflammation; Location; Necrosis; Needle biopsy procedure; Optics; Phase; Physicians; Resolution; Small Business Innovation Research Grant; Technology; Time; Translating; Ultrasonography; Validation; commercialization; improved; new technology; novel; programs; radiologist; skills; success; tumor

The long term goal of this program is to develop and translate to clinical use a novel technology that will help interventional radiologists to improve the success rate of the core needle biopsy procedures. Although ultrasound or CT are used to identify tumor location and thus to guide biopsy needle insertion, these technologies do not provide the necessary resolution to determine tumor cellularity. It is known that many tumors are heterogeneous (mixture of viable tumor, necrosis, fibrosis and inflammation), and therefore interventional radiologists encounter serious challenges when performing biopsies due to the inability of collecting sufficient or adequate material for histological analysis. As a result, biopsy success varies within a large range, from 65 to 95%, depending on the physician skills, tumor size, and biopsy location.

该计划的长期目标是开发一项新技术并将其转化为临床应用，帮助介入放射科医生提高核心针活检手术的成功率。尽管超声或 CT 用于识别肿瘤位置，从而引导活检针插入，但这些技术无法提供确定肿瘤细胞结构所需的分辨率。众所周知，许多肿瘤是异质的（活肿瘤、坏死、纤维化和炎症的混合物），因此介入放射科医生在进行活检时由于无法收集足够或足够的材料用于组织学分析而遇到严重的挑战。因此，活检的成功率差异很大，从 65% 到 95% 不等，具体取决于医生的技能、肿瘤大小和活检位置。